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The zinc finger protein glioma-associated oncogene homologue 1 (Gli-1) is a critical component of the Hedgehog (Hh) signalling
pathway, which is essential for morphogenesis and stem-cell renewal, and is dysregulated in many cancer types. As data were not
available on the role of Gli-1 expression in oesophageal cancer progression, we analysed whether it could be used to predict disease
progression and prognosis in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Among 69 patients
with histologically confirmed oesophageal squamous cell carcinomas (ESCCs), 25 showed a pathological complete response after
preoperative CRT. Overall survival (OS) was significantly associated with lymph-node metastasis, distant metastasis, and CRT, and
was further correlated with the absence of both Gli-1 nuclear expression and residual tumour. All patients with Gli-1 nuclear
expression (10.1%) had distant or lymph-node metastasis, and six out of seven died within 13 months. Furthermore, patients with
Gli-1 nuclear-positive cancers showed significantly poorer prognoses than those without (disease-free survival: mean DFS time 250 vs
1738 months, 2-year DFS 0 vs 54.9%, P¼0.009; OS: mean OS time 386 vs 1742 months, 2-year OS 16.7 vs 54.9%, P¼0.001). Our
study provides the first evidence that Gli-1 nuclear expression is a strong and independent predictor of early relapse and poor prognosis
in ESCC after CRT. These findings suggest that Hh signal activation might promote cancer regrowth and progression after CRT.
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The Hedgehog (Hh) signalling pathway plays an important role in
cell growth and differentiation, with normal roles in embryonic
pattern formation and adult tissue homoeostasis, and has a
pathological function in tumour initiation and growth including
foregut development. In addition, it regulates the response of adult
stem cells during the regeneration that takes place after tissue
damage (Ingham and McMahon, 2001; van den Brink et al, 2001;
Wetmore, 2003; Beachy et al, 2004). Secreted Hh molecules bind to
the predominant Hh receptor patched1 (Ptch1), alleviating the
Ptch-mediated suppression of smoothened (Smo), which is a
putative seven-transmembrane protein, and triggering a cascade of
intracellular events including the nuclear translocation of the zinc
finger protein glioma-associated oncogene homologue 1 (Gli-1;
Nakano et al, 1989; Aza-Blanc et al, 1997; Ruiz i Altaba, 1999;
Hooper and Scott, 2005).
Mutational activation of the Hh signalling pathway, as in
Gorlin’s syndrome, is associated with tumorigenesis in a small
subset of tissues, predominantly the skin, cerebellum, and skeletal
muscle (Johnson et al, 1996). It is also implicated in carcinogenesis
of the gastrointestinal tract as well as basal cell carcinoma,
medulloblastoma, and prostate, pancreatic, and breast cancers.
The importance of Hh signal activation has been demonstrated by
the ability of Hh pathway antagonists to suppress the growth of
gastrointestinal tumour cell lines and xenografts (Berman et al,
2003; Ma et al, 2005; Ohta et al, 2005).
Oesophageal cancer is virulent, and the presence of lymph-node
metastasis and vascular invasion indicate a high malignant
potential (Parkin et al, 2005). Surgery is the treatment of choice
for patients with locoregionally confined oesophageal cancer
(stages II and III); however, the 5-year survival rate is less than
20%, even after curative surgery (Parkin et al, 2005). Since 1996,
we have combined preoperative chemoradiotherapy (CRT) with
radical surgery for the treatment of oesophageal cancers, and have
reported increased resectability, a reduced incidence of both local
recurrence and distant metastasis, and a better prognosis for CRT
responders (Fujiwara et al, 2005). However, the benefits of CRT are
controversial, and some clinical trials have shown that this
preoperative strategy benefits only the 25% of patients who show
a pathological complete response (CR; that is, no cancer cells in the
resected specimen), whereas the remaining 75% present CRT-
resistant and highly aggressive cancers with lymph-node and
distant metastases (Coia et al, 2000; Iyer et al, 2004). Mortality
from this disease remains high because current therapies are
limited by the emergence of therapy-resistant cancer cells.
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model of solid tumour biology with a defined subset of tumour
cells harbouring stem cell-like properties of self-renewal. This
tumorigenic population of cancer cells is also characterised by
differentiation, heterogeneity, and the ability to maintain tumour
growth while playing an important role in both tumorigenesis and
resistance to therapeutics (Al-Hajj et al, 2003; Dick, 2003).
However, research has been limited because of the lack of distinct
molecular makers on these cancer progenitor cells. Aberrant Hh
pathway activation might be involved in the maintenance of such a
population in cancer, because Hh signalling regulates progenitor-
cell fate in normal development and homoeostasis.
There are no reported data on the role of Gli-1 expression, which
is a key Hh pathway target, in oesophageal cancer progression after
CRT. Moreover, the prognosis of patients undergoing CRT has not
yet been reliably estimated. The current study retrospectively
investigated the expression of Gli-1 protein in human oesophageal
squamous cell carcinoma (ESCC) tissues, and evaluated the clinical
implications of Hh signal activation for these patients who
underwent preoperative CRT and radical surgery.
PATIENTS AND METHODS
Patients and therapy
In total, 69 patients (11 women and 58 men; mean age, 60.7 years;
age range, 38–78 years) with surgically excised ESCCs were
studied at the Hyogo College of Medicine, Japan, between April
1996 and December 2005. For preoperative CRT, 5-flurouracil
(5-FU; 500mgm
 2 per day) was administered as a 120-h
continuous intravenous (i.v.) infusion starting on day 1, and
cisplatin (CDDP; 15mgm
 2 per day) was administered as a 2-h i.v.
infusion on days 1–5 (Figure 1). Radiation therapy was performed
after CDDP infusion on days 1–5 using a linear accelerator
(Mevatron KD2; Siemens, Munich, Germany) and a previously
described radiation method (Fujiwara et al, 2005). Chemotherapy
was combined with radiation therapy during the first week, and
then radiation therapy alone was repeated for the next 3 weeks
(days 8–12, 15–19, and 22–26). Each single dose of radiation was
2Gy per day, giving a total dose of 40Gy. Surgery was usually
performed 4–6 weeks after the completion of CRT. Follow-up
information was obtained from office charts, hospital records, and
telephone interviews. The ethics committee of the institution
approved the study protocol.
Evaluation prior to surgery
Approximately 2–4 weeks after the completion of CRT, patients
underwent a complete staging workup according to Response
Evaluation Criteria in Solid Tumours guidelines. Patients were
considered to have clinical CR to CRT if no residual tumour was
detected at endoscopy and if no occurrence of metastatic disease
was identified on computed tomography scan evaluation, and to
have partial response if at least a 30% decrease in the sum of the
longest diameter of target lesions.
Immunohistochemistry
Oesophageal squamous cell carcinoma tissue specimens were cut
open longitudinally, fixed with formalin, and then processed using
conventional procedures. Sections were heated for 20min at 981C
in 10mmoll
 1 sodium citrate (pH 6.0) for antigen retrieval. They
were then incubated with goat polyclonal antibody against human
Gli-1 (C-18; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
visualised with the Envision kit (Dako Cytomation, Glostrup,
Denmark). Alternative primary antibodies included goat poly-
clonal anti-human cyclooxygenase (COX)-2 antibody, mouse
monoclonal anti-human vascular endothelial growth factor
(VEGF) antibody (Santa Cruz Biotechnology), and mouse mono-
clonal anti-human chemokine (C-X-C motif) receptor 4 (CXCR4)
antibody (R&D systems, Minneapolis, MN, USA). Slides were
developed with 3,30-diaminobenzidine tetrahydrochloride solution
containing 1mll
 1 H2O2, lightly counterstained with haematox-
ylin, and then mounted. Normal mouse immunoglobulin G (IgG)
was substituted for the primary antibody as a negative control.
Sections were examined microscopically by two of the authors (LT
and TT) without knowledge of clinicopathological features. The
results of nuclear expression were graded on a five-point scale
based on the percentage of specific tumour-cell staining as follows:
no specific staining ( ); o5% of the tumour cells (±); X5t o
o35% of the tumour cells (þ); X35 to o65% of the tumour cells
(þþ); and X65% tumour cells (þþþ). Subtle expression was
defined as o5% of the tumour cells (±).
Statistical analysis
Overall survival (OS) was defined as the time from the initial
diagnosis to either the patient’s death or the date of the last
available information on vital status. Disease-free survival (DFS)
was defined as the length of time after treatment during which no
cancer was found. In univariate analysis, the difference between
the cumulative survival rates of the patient groups was calculated
by the log-rank test for comparison using Kaplan–Meier survival
curves. Statistical significance was considered at values of Po0.05.
Statistical analyses were carried out using STATISTICA statistical
software, version 06J (STATISTICA, Tulsa, OK, USA).
RESULTS
Patient and tumour characteristics
The patient characteristics are summarised in Table 1. The patient
gender bias was male (male/female¼58:11). The tumour histology
was ESCC in all cases, with 67 tumours (97.1%) originating in the
thorax. According to the tumour-node metastasis system of the
American Joint Committee on Cancer, stage II tumours were seen in
29 patients (42.0%), stage III tumours were seen in 26 patients
(37.7%), and stage IV tumours were seen in 14 patients (20.3%). In
total, 29 patients (42.0%) had lymph-node metastasis at the time of
diagnosis. All lesions before CRT presented with a T3 or T4 extent of
invasion. Three-quarters of the patients had tumours that were
between 6 and 8cm in diameter. An Mþ classification was described
in 14 tumours (M1a in six patients and M1b in eight patients). Seven
patients had distant metastasis of the liver. All patients experienced a
disease-free period. During the follow-up period, 10 patients (14.5%)
developed local recurrence or residual tumours, eight patients
(11.6%) developed neck or coeliac lymph-node recurrence, and 14
patients (20.3%) developed distant metastasis. In total, 33 patients
(47.8%) died during follow-up; among these, 29 patients (42.0%) died
from their tumours, whereas the remaining five patients (7.2%) were
tumour-free and died of intercurrent diseases.
(20 mg per body, 2 h drip)×5 days
(750 mg per body, 24 h continous)×5 days
CDDP
5-FU
Radiation Radiation Radiation Radiation
The radiation field: 3 cm longitudinal margin and 4 cm 
lateral margin
2 Gy×5 days×4 weeks=total 40 Gy
1 2 3 4 8–10
weeks
Operation
Figure 1 Schedule of preoperative CRT.
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poor prognosis
Twenty-five tumours were totally eradicated by CRT, resulting in
an absence of visible tumour cells: a pathological complete CR.
Gli-1 expression was absent in 12 tumours (17.4%) but present in
31 tumours (44.9%), seven (10.1%) of which were nuclear and 26
(37.7%) of which were cytoplasmic. In the tumours with Gli-1
nuclear expression, two were scored as (±), two were scored as
(þ), three were scored as (þþ), and none were scored as
(þþþ) (Figure 2). All seven Gli-1 nuclear-positive cancers
expressed CXCR4, COX-2, and VEGF. In total, 14 out of 69 patients
(20.3%) showed positive expressions of all three markers. All
patients with Gli-1 nuclear expression had distant or lymph-node
metastasis, and six of the seven died within 13 months. Even the
3.0% of patients who were scored as (±) died of lung or neck
lymph-node metastasis within 10 months of surgery. In the Gli-1
nuclear expression group, recurrences were found in all seven
patients; these were local in three cases and distant (in the liver,
bone, lung, and neck lymph nodes) in four cases. In contrast, in
the Gli-1-null or cytoplasmic expression or no residual tumour
group (n¼62), recurrences were found in 22 patients (in the liver,
bone, lung, neck lymph nodes, and thyroid gland). Statistical
analysis showed that distant recurrence was more common in the
patients with Gli-1 nuclear expression (P¼0.002, hazard ratio
4.115, 95% confidence interval (CI) 1.676–10.104). The univariate
analysis of the OS prognostic factors is summarised in Table 2.
Lymph-node metastasis and distant metastasis had a significant
prognostic value (P¼0.0001, P¼0.0001, respectively). Further-
more, patients showing effect of CRT revealed significantly better
OS prognosis compared to those without it (P¼0.0001).
Kaplan–Meier analysis suggested that the prognosis was
particularly unfavourable for patients with Gli-1 nuclear expres-
sion in their primary tumours, compared with the Gli-1-null or
cytoplasmic expression patients or those with no residual tumour.
The mean DFS time of the Gli-1 nuclear expression group was
250.8±38.7 months (95% CI 174.9–326.8 months) compared with
1734.8±212.2 months (95% CI 1318.8–2150.8 months) for the
Gli-1-null or cytoplasmic expression or no residual tumour group
(Figure 3; P¼0.009); the mean OS times for these groups were
386.7±116.6 months (95% CI 158.1–615.3 months) and
1742.7±208.5 months (95% CI 1334.2–2151.3 months), respec-
tively (Figure 4; P¼0.001). The 1-year, 2-year, and 3-year DFS
rates for the Gli-1 nuclear expression group vs the Gli-1-null or
Table 1 Patient characteristics
Characteristics n
Sex (male/female) 69 (58/11)
Mean age, years (range) 60.7 (38–76)
Location of tumour
Cervix 2
Upper thorax 8
Middle thorax 39
Lower thorax 20
T-classification
T3 40
T4 29
N-classification
N0 40
N1 29
M-classification
M0 55
M1 14
UICC TNM stage
IIa 29
III 26
IVa 7
IVb 7
TNM¼tumour-node metastasis; UICC¼International Union Against Cancer.
a1
a2
b1
b2
Figure 2 Immunohistochemical detection of Gli-1 in ESCC specimens. (A) Subtle nuclear expression for Gli-1 (a1,  20; a2,  200). (B) Strong nuclear
expression for Gli-1 (b1,  20; b2,  200). Bars indicate 1mm ( 20) or 100mm( 200).
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68.9%, 0 vs 54.9%, and 0 vs 47.8%, respectively; the corresponding
1-year, 2-year, and 3-year OS rates were 33.3 vs 82.8%, 16.7 vs
54.9%, and 0 vs 46.1%.
DISCUSSION
Our previous studies showed that persistent positive CXCR4,
COX-2, or VEGF expression could predict earlier recurrence in
ESCC patients after CRT. Furthermore, CXCR4 expression could
predict shorter OS period (Koishi et al, 2006; Yoshikawa et al,
2007). These findings suggested that metastatic behaviour was
determined, at least in part, by chemokine networks or micro-
vasculature on the surface of tumour cells in response to external
therapeutic intervention (ie, CRT). Intriguingly, our data showed
that Gli-1 nuclear expression, Hh signal activation, as well as
CXCR4 expression were more important than COX-2 or VEGF
expressions in tumour relapse and prognosis after CRT, whereas
appropriate postoperative chemotherapy could improve the OS
period even after the disease progression associated with COX-2 or
VEGF expression. Gli-1 nuclear expression after CRT might
therefore be a useful and reliable biomarker for the screening
and management of high-risk patients with poorer prognosis. To
date, this is the first report to demonstrate the prognostic
importance of Hh signal activation in ESCC patients undergoing
CRT, the application of Gli-1 analysis to all post-CRT ESCC
patients, and its utilisation in the planning of therapeutic
strategies. In some cases, supportive care emphasising quality of
life rather than aggressive anti-cancer therapy might be recom-
mended to high-risk patients with Hh signal activation.
Increased understanding of the importance of morphogens as
stem-cell markers allows a more targeted approach to therapy for
individual tumours. In normal tissues, Hh-induced progenitor-cell
proliferation is transient and tightly regulated, resulting in acute
epithelial repair and regeneration after injury (Beachy et al, 2004).
In contrast, aberrant activation of tumour Hh signalling cascades
is not controlled by regulatory mechanisms, leading to support
survival of tumour clonogens and tumour regrowth after CRT in
an autocrine–paracrine manner. These tumorigenic populations
of ‘more aggressive’ cancer cells that can initiate relapse and
maintain disease are explained by the ‘cancer stem cell’ concept,
but not by the stochastic carcinogenesis model, in which cells from
a heterogeneous tumour are each able to randomly give rise to new
cancers. In the hierarchical cancer stem cell model, only a small
group of undifferentiated or poorly differentiated cells, represent-
ing less than 5% of the total tumour mass, can repopulate. The
proof of this concept for cancer-initiating cells has been
established in various malignancies including acute myelogenous
leukaemia, and breast and brain cancers (Lapidot, 1994; Al-Hajj
et al, 2003; Singh et al, 2004).
In the current study, even patients with Gli-1 nuclear (±)
expressing cancers (2.9%) died from distant metastasis within a
few months. Our results also suggest that Gli-1 activation is more
important than the abovementioned parameters in orientating
tumour biology and prognosis after CRT. Indeed, postoperative
Table 2 Univariate analysis of prognostic factors for OS
Covariate n Hazard ratio 95% CI P-value for OS
Age (years)
o70 54 0.984 0.448–2.160 0.968
X70 15
Gender
Male 58 0.456 0.161–1.291 0.139
Female 11
Effect of CRT
Effective 49 0.207 0.104–0.413 0.0001***
Not effective 20
Lymph-node metastasis
Positive 31 3.567 1.751–7.266 0.0001***
Negative 38
Distant metastasis
Positive 13 4.064 2.016–8.192 0.0001***
Negative 56
Depth of tumour invasion
T3 40 0.383 0.195–0.751 0.005*
T4 29
Tumour location
a
Upper 10 1.139 0.442–2.934 0.787
Lower 59
Gli-1 expression
Nuclear 7 4.115 1.676–10.104 0.002**
Others 62
CI¼confidence interval; CRT¼chemoradiotherapy; Gli-1¼glioma-associated on-
cogene homologue 1; OS¼overall survival. *Po0.01; **Po0.005; ***Po0.0005.
aUpper or lower, above or below the tracheal bifurcation.
Log-rank test: P=0.009
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Figure 3 Disease-free survival differences between patients with nuclear
Gli-1 expression and patients with no residual tumour and Gli-1-null or
cytoplasmic expression.
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Figure 4 Overall survival differences between patients with Gli-1 nuclear
expression and patients with no residual tumour and Gli-1-null or
cytoplasmic expression.
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with Gli-1 nuclear-positive tumours. Any therapeutic intervention
could not arrest the disease progression in association with Hh
signal activation. These results suggest that Hh signal activation
might promote cancer regrowth and progression after CRT, and
that subtle Gli-1 activation after CRT is indicative of the emergence
of ‘more aggressive’ cancer cells. The functional properties of such
cells might be influenced through external signals, including those
that can affect migratory potential and are mediated by further-
differentiated cancer cells and host stromal cells. The signals that
can influence migratory potential are thought to result in highly
aggressive cancer forms, and thereby contribute to cancer
recurrence. In this paper, the effect of CRT on Gli-1 expression
was not revealed. A recent report has shown that Gli-1 was
expressed in a half of ESCC patients’ specimens (Mori et al, 2006).
Our results suggested that Gli-1 expression with CRT was less than
that without it (10.1 vs 50.0%), and that Hh activation even after
CRT correlated with earlier relapse and treatment resistance. As
expected, all Gli-1 nuclear-positive cancers in the current study
expressed CXCR4, COX-2, and VEGF, which was indicative of a
cancer progenitor cell-like surface characteristic that might
contribute to cancer relapse and treatment failure.
Our current study focused on the novel therapeutic targeting
of distinct oncogenic signalling elements activated in cancer
progenitor cells and their local microenvironment. Recently, a
combination of gemcitabine and small-molecule Smo inhibitor
cyclopamine has been shown to abrogate metastases in pancreatic
cancer xenografts, whereas gemcitabine alone reduced the size of
primary ‘bulk’ tumours (Feldmann et al, 2007). The efficacious
blockade of Hh cascades activated in cancer progenitor cells
during tumour progression shows promise for improving current
clinical treatments against high-risk, metastatic, or relapsed ESCC.
Future clinical application of Hh pathway antagonists such as
cyclopamine and arsenic trioxide should be explored.
In summary, we showed that the monoclonal amplification of
Gli-1 nuclear localisation implicating Hh pathway activation was
correlated with oesophageal cancer progression, and that subtle
Hh cascade activation after CRT indicated early cancer progenitor
cell emergence. Although the functional and clinical significance of
the Hh pathway remains to be elucidated, we suggest that Gli-1
expression is a link between relapse and CRT-resistant cancer cells,
and is thus a potential diagnostic biomarker and therapeutic
target.
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